Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company’s current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, APC-2000 for the treatment of bronchospasms, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. Adamis’ goal is to create low-cost therapeutic alternatives to existing treatments. Consistent across all specialty pharmaceuticals product lines, Adamis intends to submit Section 505(b)(2) New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) whenever possible in order to potentially reduce the time to market and to save on costs, compared to those associated with Section 505(b)(1) NDAs for new drug products. The company was founded in 2006 and is headquartered in San Diego, California.

Corporate Information

Headquarters:
Adamis Pharmaceuticals Corporation
11682 El Camino Real, Suite # 300
San Diego, CA 92130
Phone: 858-997-2400
  Investor Relations and Media Contact:
Mark Flather
Director, Investor Relations and Corporate Communications
Phone: 858-412-7951
Email: mflather@adamispharma.com
 
Transfer Agent:
First American Stock Transfer
4747 N. 7th Street, Suite # 170
Phoenix, AZ 85014
Phone: 602-485-1346
Fax: 602-788-0423
www.firstamericanstock.com
  Independent Auditor:
Mayer Hoffman McCann P.C.
http://www.mhm-pc.com

Attorneys:
Weintraub Tobin Chediak Coleman Grodin
www.weintraub.com

Forward-Looking Statement
This website includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts, but are based on current expectations, assumptions, estimates and beliefs about our company and our industry. These statements are often, but not always, made through the use of word or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," and "would." Statements throughout this website concerning future events depend on several factors beyond the company's control, including receipt of adequate funding to support these activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, one or more of which may cause our actual results to be materially different from the forward-looking statements contained throughout this website.

Forward-looking statements contained on this website may include, but are not limited to, statements about our product candidates, research and development, strategies, objectives regulatory matters, markets, and future performance, future financial and operating results, the company's ability to obtain adequate funding to support its operations, the company's beliefs concerning the safety and effectiveness of its compounds and drug product candidates, the expected timing and outcome of future clinical trials of the company's product candidates, the expected timing and outcome of submissions to the FDA or other regulatory agencies for approvals to conduct clinical trials or for marketing approvals for our products, future revenues from sales of products, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities, the current or future market sizes for the company's products, the extent of customer demand for the company's products, and the intellectual property protection that may be afforded by any patents or patent applications relating to the company's products, product candidates and technologies. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: Adamis' inability to obtain required funding, which could delay or prevent research, development and commercialization of its products; unexpected or adverse outcomes or developments at the FDA or other regulatory agencies; the impact of legislation that could affect the pharmaceutical industry; future clinical trials may not demonstrate the safety or effectiveness of its product candidates; market demand for Adamis' products may be materially different from expectations; patents and intellectual property may not be effective to protect Adamis' rights in its products or prevent other from developing competing products, or third parties may have patents or intellectual property that restrict Adamis' ability to commercialize and sell products; and Adamis' exposure to litigation and unexpected outcomes in litigation. Additional risks not known to Adamis or that Adamis believes are immaterial may also adversely affect its business, operating results and financial condition.

A more complete description of these and other risks and uncertainties that could cause actual results and events to differ materially from the outcomes anticipated by forward-looking statements is set forth under the caption "Risk Factors" contained in our annual report on Form 10-K (Part I, Item 1A) and in other reports Adamis files with the with the Securities and Exchange Commission (SEC), which are available at the SEC's Internet site (www.sec.gov). Adamis strongly urges you to read and consider each of those factors when evaluating the forward-looking statements.

No Duty to Update
The company assumes no duty to update the information contained in this website to reflect subsequent developments or to update any forward-looking statement contained in the website, except as may be required by applicable law.


Data provided by Nasdaq. Minimum 15 minutes delayed.